Denver, CO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- CB Scientific, Inc. (OTC PINK: CBSC), a designer, developer and manufacturer of Cannabis Analytical Tools and Devices, Cannabis Medical Delivery Systems and Personal Analytical Kits and Devices. The company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. CB Scientific announces today that the Company’s 2018 R & D goals focused on products and technologies to address opioid crisis.
President Trump on October 26 directed the Department of Health and Human Services to declare the opioid crisis a public health emergency, taking long-anticipated action to address a rapidly escalating epidemic of drug use. United States is in the middle of an unprecedented opioid epidemic; Since 2000, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.
Studies have shown that phyto-cannabinoids like Cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. CB Scientific’s studies have shown that Cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. CB Scientific has been developing various cannabinoid delivery technologies and state-of-the art smart medical devices for relieving various pains and opioid withdrawal symptoms. There is strong evidence that cannabinoid compounds can relieve from depression caused by drug addiction. CB Scientific is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of PainPatchTM for opioid addiction.
“Data is showing that on an average day in US about 140 people die from an opioid-related overdose, most of the ones died belongs to the younger population” said Bobban Subhadra, M.S., Ph.D, Chief Operating Officer of CB Scientific. “This is a serious epidemic that need to be dealt with a high level of urgency; we are talking about teens who are the future of our nation dying in high numbers on our streets. That is the reason, why we at CB Scientific, wanted to seriously investing in the application of our PainPatch as a possible intervention for opioid addiction. Even if we can save one young life with our technology, we will take it as an enormous success” he added.
About CB Scientific, Inc.
CB Scientific (www.cbscientific.com), through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, Medical Delivery Systems, laboratory services, personal analytical kits and devices and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific is continuing to develop new technologies specifically for cannabis (hemp) analytics. CB Scientific believes every product sold to patients as "Medical Quality" should be inspected for health benefits, safety, consistency, purity, potency and packaged properly for distribution. CB Scientific has worked with many of the cannabis industry leaders in the country and have also been featured in cannabis industry publications including High Times Magazine, Culture and many trade publications, on-air interviews and panel discussions across the United States. CB Scientific's focus has been the education and safety of consumers combined with innovation to put power into the hands of the patients.
To request further information about CB Scientific, please email us at firstname.lastname@example.org, log onto our website at http://www.cbscientific.com or visit us on Twitter @cbscientific and Facebook at cbscientificinc.
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Source:CB Scientific Inc